← Leaderboards
Margaret E. Wierman
University Of Colorado Denver
$2,782,131
Attributed
$2,782,131
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $377.2K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,782,131 · 5
VA$0 · 2
By mechanism
R01$2,777,398 · 2
M01$4,733 · 3
I01$0 · 2
Top collaborators
- Katja Kiseljakvassiliades2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Katja Kiseljakvassiliades$1,049,975
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsCell LineCellsGenesIn VivoMutationCell ModelPhenotypeDatabasesProteinsPhosphotransferasesPathogenesisMouse ModelKinase InhibitorNovel TherapeuticsGenomicsLightOperative Surgical ProceduresMalignant NeoplasmsNude MiceAnimal ModelCell ProliferationOverexpressionResponse
Grant awards (25)
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2024 · VA
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2023 · VA
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2022 · VA · contact PI
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2021 · VA · contact PI
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2020 · VA · contact PI
Targeting Kinases in Novel Preclinical Models of Adrenocortical Carcinoma$0
I01 · FY2019 · VA · contact PI
Role of the Sterile20 (Ste20)-like kinase MST4 in Pituitary Tumorigenesis$0
I01 · FY2017 · VA · contact PI
Role of the Sterile20 (Ste20)-like kinase MST4 in Pituitary Tumorigenesis$0
I01 · FY2016 · VA · contact PI
Role of the Sterile20 (Ste20)-like kinase MST4 in Pituitary Tumorigenesis$0
I01 · FY2015 · VA · contact PI
Role of the Sterile20 (Ste20)-like kinase MST4 in Pituitary Tumorigenesis$0
I01 · FY2014 · VA · contact PI
Novel Factors that Regulate GnRH Neuronal Development$377,200
R01 · FY2010 · HD · contact PI
CONT PSTV AIRWAY PRESS&INSLN SENSITIZATION W/ROSIG ON ERECTILE DYSFNCTN W/APNEA$237
M01 · FY2008 · RR · contact PI
Novel Factors that Regulate GnRH Neuronal Development$276,838
R01 · FY2007 · HD · contact PI
CONT PSTV AIRWAY PRESS&INSLN SENSITIZATION W/ROSIG ON ERECTILE DYSFNCTN W/APNEA$2,020
M01 · FY2007 · RR · contact PI
Novel Factors that Regulate GnRH Neuronal Development$276,838
R01 · FY2006 · HD · contact PI
CONT PSTV AIRWAY PRESS&INSLN SENSITIZATION W/ROSIG ON ERECTILE DYSFNCTN W/APNEA$2,476
M01 · FY2006 · RR · contact PI
Novel Factors that Regulate GnRH Neuronal Development$283,500
R01 · FY2005 · HD
Novel Factors that Regulate GnRH Neuronal Development$283,500
R01 · FY2004 · HD
Novel Factors that Regulate GnRH Neuronal Development$283,500
R01 · FY2003 · HD
DEVELOPMENTAL CONTROL OF GNRH EXPRESSION BY POU PROTEINS$167,698
R01 · FY2002 · DK
NOVEL FACTORS THAT REGULATE GNRH NEURONAL DEVELOPMENT$163,728
R01 · FY2002 · HD
DEVELOPMENTAL CONTROL OF GNRH EXPRESSION BY POU PROTEINS$163,960
R01 · FY2001 · DK
NOVEL FACTORS THAT REGULATE GNRH NEURONAL DEVELOPMENT$163,848
R01 · FY2001 · HD
NOVEL FACTORS THAT REGULATE GNRH NEURONAL DEVELOPMENT$169,456
R01 · FY2000 · HD
DEVELOPMENTAL CONTROL OF GNRH EXPRESSION BY POU PROTEINS$167,332
R01 · FY2000 · DK